NicholasJohnMaragakisMD

Neurophysiology

Professor of Neurology, Johns Hopkins University School of Medicine; Co-director, Michael S. and Karen G. Ansari ALS Center for Cell Therapy and Regeneration Research

Join to view full profile

Dr. Maragakis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Maragakis' full profile

Already have an account?

Office
601 North Caroline Street
Baltimore, MD 21287
Phone+1 410-955-9441

Fax+1 410-955-6402

Education & Training

Johns Hopkins UniversityFellowship, Clinical Neurophysiology, 1998 - 1999
Johns Hopkins UniversityResidency, Neurology, 1995 - 1998
University of Utah HealthInternship, Internal Medicine, 1994 - 1995
University of Utah School of MedicineClass of 1994

Certifications & Licensure

MD State Medical License 1998 - 2025
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2012 Jan 01
Completed
Not Applicable
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Start of enrollment: 2015 Jun 01
Completed
Phase 2
Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS Start of enrollment: 2020 May 28
RECRUITING
PHASE2, PHASE3
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation Start of enrollment: 2021 May 17
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

ALSUntangled #78: Zinc.
Benjamin Helmold, George Nathaniel, Paul Barkhaus, Tulio Bertorini, Mark Bromberg
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2025-03-14
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
, Jeremy M Shefner, Björn Oskarsson, Eric A Macklin, Lori B Chibnik
JAMA. 2025-02-17
2 citations
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
, James D Berry, Nicholas J Maragakis, Eric A Macklin, Lori B Chibnik
JAMA. 2025-02-17

Journal Articles

Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis
Brian J Wainger, Nicholas J Maragakis, Richard Bedlack, Namita A Goyal, Seward B Rutkove, Michael H Rivner, Stephen A Goutman, Shafeeq S Ladha, Elizabeth A Mauricio, R..., JAMA Neurology
Motor Neuron-Derived microRNAs Cause Astrocyte Dysfunction in Amyotrophic Lateral Sclerosis
Jeffrey D Rothstein, Nicholas J Maragakis, Timothy M Miller, Brain

Other

Motoneuron Disease: Clinical
Nicholas Maragakis, MD, Springer
https://www.doximity.com/articles/11995bea-a048-4cec-bc0f-7564c791758a
UpToDate, Wolters Kluwer Health - 2012-10-23

Press Mentions

Clinical Research Week: Your Path to Advancing ALS ResearchJanuary 21st, 2025
What Is Pseudobulbar Affect? Symptoms, Causes, Diagnosis, Treatment, and PreventionFebruary 4th, 2023
Johns Hopkins Researchers Identify Potential Window for Treating ALSApril 8th, 2022
Join now to see all